[Oral combination chemotherapy of 5'-deoxy-5-fluorouridine (furtulon) and cyclophosphamide for advanced breast cancer].

Autor:	Xu BH; Department of Medical Oncology, Cancer Institute (Hospital), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China., Zhang YJ, Zheng X, Wu Q, Wu XT
Jazyk:	čínština
Zdroj:	Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2003 May; Vol. 25 (3), pp. 282-4.
Abstrakt:	Objective: To evaluate the efficacy and safety of the oral combination chemotherapy of furtulon (FTL) and cyclophosphamide (CTX) for advanced breast cancer (ABC). Methods: From Jun 2000 to Jun 2002, eighty-three patients with ABC were treated with the two oral drugs as combined chemotherapy. The mean number of cycles was 5, median number of cycles was 6 (range 2-6). Results: The overall response rate was 45.8%, The median time to progression was 6 months. The treatment was well tolerated, with related Grade 3 clinical adverse effect being only nausea and vomiting in 2 patients (2.4%) and mild hematologic toxicities. Conclusion: Oral combined chemotherapy of FTL and CTX, being convenient and safe, is effective for patients with advanced breast cancer.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu